Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

J Mulvey J, Matnani R, Cushing MM. Historical ABO blood group discrepancy: a blessing in disguise to unravel a medical identity theft. Transfusion. 2017;57(4):1096-1097.

Postnikoff SD, Johnson JE, Tyler JK. The integrated stress response in budding yeast lifespan extension. Microb Cell. 2017;4(11):368-375.

Khani F, Epstein JI. In response to 'a plea for greater standardization' in intraductal carcinoma of the prostate: greater standardization requires greater evidence. Histopathology. 2017;70(6):1011-1013.

Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int. 2017;91(4):787-789.

Rooper LM, Onenerk M, Siddiqui MT, Faquin WC, Bishop JA, Ali SZ. Nodular oncocytic hyperplasia: Can cytomorphology allow for the preoperative diagnosis of a nonneoplastic salivary disease? Cancer Cytopathol. 2017;125(8):627-634.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14290.

Natkunam Y, Gratzinger D, de Jong D, Chadburn A, Goodlad JR, Chan JK, et al. Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. Am J Clin Pathol. 2017;147(2):124-128.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14747.

Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78-83.

Linares JF, Cordes T, Duran A, Reina-Campos M, Valencia T, Ahn CS, et al. ATF4-Induced Metabolic Reprograming Is a Synthetic Vulnerability of the p62-Deficient Tumor Stroma. Cell Metab. 2017;26(6):817-829.e6.